Mortality Increased With Hospital-Based Care for Hallucinogen Use
By Elana Gotkine HealthDay Reporter
MONDAY, March 3, 2025 -- Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March 3 in CMAJ, the journal of the Canadian Medical Association.
Daniel T. Myran, M.D., M.P.H., from the University of Ottawa in Ontario, Canada, and colleagues conducted a retrospective cohort study using linked health administrative data for all people aged 15 years and older living in Ontario, Canada, from 2006 to 2022. Overall and cause-specific mortality risks were compared for members of the general population and those with incident acute care involving hallucinogens or other substances.
The analyses included 11,415,713 people; 0.07 percent had incident acute care involving hallucinogens. The researchers found that in a matched analysis involving 77,101 people with a median follow-up of seven years, acute care involving hallucinogens was associated with an increased risk for all-cause mortality within five years compared with the general population (absolute risks, 6.1 versus 0.6 percent; hazard ratio, 2.57). Similar elevations in risk were seen in analyses excluding people with comorbid mental or substance use disorders (hazard ratio, 3.25). Relative to the general population, people with acute care involving hallucinogens had a significantly increased risk for death by unintentional drug poisoning, suicide, respiratory disease, and cancer (hazard ratios, 2.03, 5.23, 2.46, and 2.88, respectively).
"We found that people requiring acute care for hallucinogen use are at substantially elevated risk of premature death compared with the general population," the authors write. "Despite a resurgence of interest in identifying potential therapeutic effects of hallucinogens, major gaps exist in our understanding of associated risks."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-04 06:00
Read more

- Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia
- Not Much Works To Soothe Low Back Pain, Study Says
- ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
- This Score Can Predict Risk of Early Colon Cancer
- Abnormal Uterine Bleeding Linked to Fatigue in Menopause Transition
- VA Ends Hormone Therapy for Newly Diagnosed Transgender Veterans
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions